Fig. 8

FL118 is potentially a superior anticancer drug against soft tissue sarcoma (STS): A, B FL118 (but not DOX) exhibited excellent efficacy against STS (A) with acceptable toxicity (B). The HT1080 STS cells (2 × 10⁶ per tumor site) mixed with 50% Matrigel were subcutaneously injected into 2–3 severe combined immunodeficiency (SCID) mice in the flank area to establish xenograft tumors. The established STS tumors were maintained on SCID mice. STS tumor SCID mice for the planned experimental studies were set up from the STS tumor‐maintained mice. Treatment with vehicle, DOX or FL118 at dose level of 5 mg/kg (DOX’s MTD – maximum tolerated dose) were started when tumors were grown into the size of 150—200 mm³. The schedule and route were weekly × 3 via intravenous (i.v.) administration (arrowed). A STS tumor change curves after vehicle, DOX and FL118 treatment. Each tumor curve is the mean tumor size + SD from 3 SCID mice. B Mouse body weight change curves after vehicle, DOX and FL118 treatment. Each body weight change curve is the mean body weight change + SD from 3 SCID mice. C, D FL118 exhibited high efficacy to regress STS tumors at FL118’s sub-MTD (C) with acceptable toxicity (D). HT1080 STS tumor establishment, experimental tumor mouse set up and treatment are the same as in A and B. The schedule and route were weekly × 4 via oral administration (arrowed). C STS tumor change curves after treatment with vehicle or FL118 at different dose levels as shown. Each tumor curve is the mean tumor size + SD from 3 SCID mice. D Mouse body weight change curves after treatment with vehicle or FL118 at different dose levels as shown. Each body weight change curve is the mean body weight change + SD from 3 SCID mice